CD19 and leukemia: Blinatumomab is a CD3/CD19-directed bispecific T-cell engager molecule (BiTE) that brings CD19-expressing leukemia cells and CD3-positive cytotoxic T cells together to facilitate T-cell-mediated leukemia cell killing.